The Gross Law Firm Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE

Core Points - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit related to misleading statements about the company's lead product candidate, nimacimab [1] - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, during which it is alleged that the effectiveness of nimacimab was overstated [1] - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs and receive updates on the case [2] Allegations - The complaint alleges that Skye Bioscience's management made materially false and misleading statements about nimacimab's effectiveness [1] - It is claimed that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to inflated stock prices [1] Next Steps for Shareholders - Shareholders who purchased SKYE shares during the specified class period can register to be included in the case and will receive status updates through portfolio monitoring software [2] - There is no cost or obligation for shareholders to participate in the class action [2] About the Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]